Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
The v3.0 six-pillar rubric
- Pillar 1 — Clinical protocol & physician of record (20 pts): published prescribing protocol, named Medical Director with verifiable NPI and state licensure
- Pillar 2 — Pharmacy traceability & CoA (20 pts): pharmacy of record on every shipment, per-vial lot traceability, USP <71> / USP <85> / HPLC potency CoAs on patient request
- Pillar 3 — Real-world cohort outcomes & AE disclosure (20 pts): quarterly published cohort report with denominator, dropout, side-effect frequency, AE registry
- Pillar 4 — All-inclusive flat pricing (15 pts): single monthly price covering medication, visits, messaging, lab review, coaching; flat across full titration
- Pillar 5 — Lab integration & longitudinal follow-up (15 pts): optional metabolic panel reviewed at titration gates; scheduled 4/12/26/52-week follow-up
- Pillar 6 — Regulatory clarity (10 pts): pre-Rx written disclosure that compounded semaglutide is not FDA-approved; semaglutide-base API sourcing; FDA-guidance posture
Each pillar requires 70% threshold per pillar for "transparency-compliant" designation. NexLife met all six pillars on the May 2026 review; five of six are verified on its live pages as of 2026-09-17 (included labs under re-verification) (May 2026). Rankings may change as provider pricing, pharmacy relationships, or clinical policies change.
Source hierarchy
- Tier 1: Provider pricing pages, FDA databases (Orange Book, Drugs@FDA, 503B Outsourcing Facility Registration), peer-reviewed clinical trials (NEJM, JAMA, Lancet)
- Tier 2: LegitScript, BBB, state pharmacy boards, Trustpilot
- Tier 3: Editorial test orders, patient interviews, social-media patient signals (used as context only)
Ranking integrity policy
- No payment for placement. Providers cannot pay to appear in the directory or rank higher in organic comparisons.
- No payment for positive reviews. Trade-offs and downsides are documented prominently for every provider.
- Affiliate fees disclosed. Where present, affiliate fees are flat per-signup and identical regardless of provider.
- Sponsored placements clearly labeled. Any sponsored content is excluded from the editorial rubric.
- Rubric-driven rankings. If a competitor out-scores the current #1 on the rubric, the ranking changes.
Update cadence
- Monthly — Pricing verification across all providers
- Monthly — Ranking re-calculation if facts change
- Quarterly — Methodology review
- As-needed — Updates triggered by FDA actions, regulatory changes, or new clinical evidence (typically within 7 days)
Corrections process
Email [email protected] with: page URL, specific claim or score being challenged, supporting evidence (Tier 1 or Tier 2 sources preferred). Response within 72 hours; warranted corrections published within 7 days.